A Review of its Clinical Use in the Treatment of Anaemia in Patients with Cancer

Drugs

Volumn 64, Issue 3, 2004, Pages 323-346

  Cheer, Susan M ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Anaemia; Cancer; Epoetin beta; Pharmacodynamics; Pharmacokinetics; Recombinant human erythropoietin; Therapeutic use

Indexed keywords

CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; ETOPOSIDE; HEMOGLOBIN; PLACEBO; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ANEMIA; BLOOD TRANSFUSION; BONE PAIN; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; DRUG UTILIZATION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; INJECTION PAIN; INJECTION SITE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; OVARY CANCER; PNEUMONIA; PREDICTION; QUALITATIVE ANALYSIS; QUALITY OF LIFE; REVIEW; SEPTICEMIA; SIDE EFFECT; SKIN MANIFESTATION; SOLID TUMOR; THROMBOCYTE COUNT; TREATMENT INDICATION; CHEMICALLY INDUCED DISORDER; HALF LIFE TIME; NEOPLASM; SUBCUTANEOUS DRUG ADMINISTRATION;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; NEOPLASMS; QUALITY OF LIFE;

EID: 1442277118     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464030-00006     Document Type: Review

References (80)

1. Ludwig H. Epoetin in cancer-related anaemia. Nephrol Dial Transplant 1999; 14 Suppl. 2: 85-92
2. Griggs JJ, Blumberg N. Recombinant erythropoietin and blood transfusions in cancer chemotherapy-induced anemia. Anticancer Drugs 1998; 9: 925-32
3. Beguin Y. Prediction of response to optimize outcome of treatment with erythropoietin. Semin Oncol 1998 Jun; 25 (3 Suppl. 7): 27-34
4. Del Mastro L, Gennari A, Donati S. Chemotherapy of non-small-cell lung cancer: role of erythropoietin in the management of anemia. Ann Oncol 1999; 10 Suppl. 5: S91-4
5. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999 Oct 6; 91 (19): 1616-34
6. Engert A. Recombinant human erythropoietin as an alternative to blood transfusion in cancer-related anaemia. Dis Manage Health Outcomes 2000 Nov; 8 (5): 259-72
7. Thomas ML. Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Med Oncol 1998 Aug; 15 Suppl. 1: S3-7
8. Abels RI. Use of recombinant human erythropoietin in the treatment of anaemia in patients who have cancer. Semin Oncol 1992; 19 (3 Suppl. 8): 29-35
9. Cella D. Factors influencing quality of life in cancer patients: anemia and fatigue. Semin Oncol 1998 Jun; 25 (3 Suppl. 7): 43-6
10. Henry DH. Recombinant human erythropoietin treatment of anemic cancer patients. Cancer Pract 1996; 4 (4): 180-4
11. Cella D, Bron D. The effect of epoetin alfa on quality of life in anemic cancer patients. Cancer Pract 1999; 7 (4): 177-82
12. Beguin Y. A risk-benefit assessment of epoetin in the management of anaemia associated with cancer. Drug Saf 1998 Oct; 19 (4): 269-82
13. Jelkmann W. Biology of erythropoietin. Clin Investig 1994; 72: S3-S10
14. Dunn CJ, Markham A. Epoetin beta: a review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure [published erratum appears in Drugs 1996 May; 51 (5): 894], Drugs 1996 Feb; 51 (2): 299-318
15. Krantz SB. Erythropoietin. Blood 1991 Feb 1; 77 (3): 419-34
16. Ehmer B, Scigalla P. Erythropoietin as a therapeutic agent. Quintessenzen Der Medezin 1994; 2 (1): 25-37
17. Fisher JW. Erythropoietin: physiologic and pharmacologic aspects. Proc Soc Exp Biol Med 1997; 216: 358-69
18. Zaché P. Controversies in selection of epoetin dosages: issues and answers. Drugs 1995; 49 (4): 536-47
19. Erslev AJ. Erythropoietin. N Engl J Med 1991 May 9; 324 (19): 1339-44
20. Nissenson AR. Erythropoietin overview - 1993. Blood Purif 1994; 12 (1): 6-13
21. Koeller JM. Clinical guidelines for the treatment of cancer-related anemia. Pharmacotherapy 1998; 18 (1): 156-69
22. Nowrousian MR. Recombinant human erythropoietin in the treatment of cancer-related or chemotherapy-induced anaemia in patients with solid tumours. Med Oncol 1998; 15 Suppl. 1: S19-28
23. Flaharty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47: 557-64
24. Abraham PA, Halstenson CE, Macres MM, et al. Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies. Clin Pharmacol Ther 1992; 52: 205-13
25. Halstenson CE, Macres M, Katz SA, et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50 (6): 702-12
26. Ponchio L, Beguin Y, Farina G, et al. Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 1992; 77: 494-501
27. Kaupke CJ, Vaziri ND, Sampson JR, et al. Effect of erythropoietin therapy on diet and dialysis clearances in hemodialysis patients. Int J Artif Organs 1990; 13 (4): 218-22
28. Kaizu K, Uriu K, Eto S. Effects of recombinant human erythropoietin (EPOCH) on the coagulation and fibrinolytic systems and platelet function in pre-dialysis patients with chronic renal failure. Nippon Jinzo Gakkai Shi 1993; 35 (8): 989-97
29. Bennett WM. A multicenter clinical trial of epoetin beta for anemia of end-stage renal disease. J Am Soc Nephrol 1991; 1 (7): 990-8
30. Macdougall IC, Davies ME, Mutton RD, et al. Rheological studies during treatment of renal anaemia with recombinant human erythropoietin. Br J Haematol 1991 Apr; 77 (4): 550-8
31. Boogaerts M, Coiffier B, Kainz C, et al. Impact of epoetin β on quality of life in patients with malignant disease. Br J Can 2003; 88: 988-95
32. Tsukuda M, Yuyama S, Kohno H, et al. Effectiveness of weekly subcutaneous recombinant human erythropoietin administration for chemotherapy-induced anemia. Biotherapy 1998; 11 (1): 21-5
33. Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995 Dec 15; 86 (12): 4446-53
34. Glimelius B, Linné T, Hoffman K, et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol 1998 Feb; 16 (2): 434-40
35. Österborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002 May 15; 20 (10): 2486-94
36. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2 (4): 927-36
37. Imai Y, Sekino H, Fujikura Y, et al. Pressor effect of recombinant human erythropoietin: results of ambulatory blood pressure monitoring and home blood pressure measurements. Clin Exp Hypertens 1995; 17 (3): 485-506
38. Hand MF, Haynes WG, Johnstone HA, et al. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48: 806-13
39. Li PKT, Leung CB, Lui SF, et al. Correction of anemia using self-administered daily subcutaneous erythropoietin in uremic patients on continuous ambulatory peritoneal dialysis. Int J Artif Organs 1993; 16 (7): 510-4
40. Macdougall IC, Lewis NP, Saunders MJ, et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990 Mar 3; 335: 489-93
41. Wizemann V, Kaufmann J, Kramer W. Effect of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161-5
42. Österborg A, Boogaerts MA, Cimino R, et al. Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma: a randomized multicenter study. Blood 1996 Apr 1; 87 (7): 2675-82
43. Taylor JE, Belch JJF, McLaren M, et al. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in haemodialysis patients. Kidney Int 1993; 44: 182-90
44. Faulds D, Sorkin EM. Epoetin (recombinant human erythropoietin): a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in anaemia and the stimulation of erythropoiesis. Drugs 1989 Dec; 38 (6): 863-99
45. Roche Products Limited. NeoRecormon multi-dose 50,000 IU powder and solvent for injection. Package leaflet [online]. Available from URL: http://emc.medicines.org.uk [Accessed 2003 Nov 26]
46. Frenken LAM, van Lier HJJ, Gerlag PGG, et al. Assessment of pain after subcutaneous injection of erythropoietin in patients receiving haemodialysis. BMJ 1991 Aug 3; 303 (6806): 288
47. Lui SF, Leung CB, Li PKT, et al. Pain after subcutaneous injection of erythropoietin [abstract]. BMJ 1991 Oct 5; 303 (6806): 856
48. Hendriks MWG, Peters FPJ, Hooymans PM, et al. Is Recormon® less painful than Eprex® after subcutaneous administration? Pharm Weekbl Sci 1992; 14 (2): 55-8
49. Morris KP, Hughes C, Hardy SP, et al. Pain after subcutaneous injection of recombinant human erythropoietin: does Emla cream help? Nephrol Dial Transplant 1994; 9: 1299-301
50. Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992; 12: 68-72
51. Boyce MD, Warrington SJ. A comparison of the discomfort of subcutaneous injections of epoetin beta and phosphate-buffered epoetin alfa. Br J Clin Res 1995; 6: 213-7
52. Kampf D, Eckardt KU, Fischer HC, et al. Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 1992; 61: 393-8
53. Stockenhuber F, Loibl U, Gottsauner-Wolf M, et al. Pharmacokinetics and dose response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 399-402
54. Neumayer H-H, Brockmöller J, Fritschka E, et al. Pharmacokinetics of recombinant human erythropoietin after SC administration and in long-term IV treatment in patients on maintenance haemodialysis. Contrib Nephrol 1989; 76: 131-42
55. Macdougall IC, Roberts DE, Neubert P, et al. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989 Feb 25; 1 (8635): 425-7
56. Jensen JD, Madsen JK, Jensen LW, et al. Pharmacokinetics of epoetin in dialysis patients before and after correction of the anaemia. Drug Invest 1994; 8 (5): 278-87
57. Kindler J, Eckardt K-U, Ehmer B, et al. Single-dose pharmacokinetics of recombinant human erythropoietin in patients with various degrees of renal failure. Nephrol Dial Transplant 1989; 4: 345-9
58. Spivak JL, Hogans BB. The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 1989 Jan; 73 (1): 90-9
59. Weintraub AH, Gordon AS, Becker EL, et al. Plasma and renal clearance of exogenous erythropoietin in the dog. Am J Physiol 1964; 207: 523-9
60. Emmanouel DS, Goldwasser E, Katz AI. Metabolism of pure human erythropoietin in the rat. Am J Physiol 1984; 247: F168-76
61. Rosse WF, Waldmann TA. The metabolism of erythropoietin in patients with anemia due to deficient erythropoiesis. J Clin Invest 1964; 43 (7): 1348-54
62. Jensen JD, Madsen JK, Jensen LW, et al. Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 1994; 5: 177-85
63. Jensen JD, Jensen LW, Madsen JK, et al. The metabolism of erythropoietin in liver cirrhosis patients compared with healthy volunteers. Eur J Haematol 1995; 54: 111-6
64. Jensen JD, Jensen LW, Madsen JK. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. Eur J Clin Pharmacol 1994; 46: 333-7
65. Macdougall IC, Jones JM, Robinson MI, et al. Subcutaneous erythropoietin therapy: comparison of three different sites of injection. Contrib Nephrol 1991; 88: 152-6
66. Cazzola M, Beguin Y, Kloczko J, et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous er-ythropoietin production. Br J Haematol 2003; 122: 386-93
67. Glossmann J-P, Engert A, Wassmer G, et al. Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy - results of a randomized trial. Ann Hematol 2003; 82: 469-75
68. Oberhoff C, Neri B, Amadori D, et al. Recombinant human erythropoietin in the treatment of chemotherapy-induced anemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998; 9: 255-60
69. ten Bokkel Huinink WW, de Swart CAM, van Toom DW, et al. Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapy. Med Oncol 1998; 15: 174-82
70. Johansson J-E, Wersäll P, Brandberg Y, et al. Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer. Scand J Urol Nephrol 2001; 35: 288-94
71. Olsson A-M, Svensson J-H, Sundström J, et al. Erythropoietin treatment in metastatic breast cancer: effects on Hb, quality of life and need for transfusion. Acta Oncol 2002; 41 (6): 517-24
72. Kunikane H, Watanabe K, Fukuoka M, et al. Double-blind randomized control trial of the effect of recombinant human erythropoietin on chemotherapy-induced anemia in patients with non-small cell lung cancer. Int J Clin Oncol 2001; 6: 296-301
73. Wumig C, Windhager R, Schwameis R, et al. Prevention of chemotherapy-induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double-blind, randomized, phase III study). Transfusion 1996; 36 (2): 155-9
74. Bottomley A, Thomas R, van Steen K, et al. Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about? Lancet Oncol 2002 Mar; 3: 145-53
75. Ismagilov RZ, Koolmagambetov IR, Yusumbaeva AS, et al. Influence of anemia treatment in patients with chronic renal failure by Recormon on acid-base condition [abstract]. Nephrology 1997 May; 3: 188
76. Thomas ML. Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Med Oncol 1998 Aug; 15 Suppl. 1: S13-8
77. Henke M, Laszig R, Rübe C, et al. Erythopoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003 Oct 18; 362: 1255-60
78. Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized, phase m trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002 Aug 21; 94 (16): 1211-20
79. Stephenson J. Erythropoietin boost survival after radiotherapy [journal note]. Lancet Oncol 2001; 2 (12): 711
80. Weinberg ED. Iron therapy and cancer. Kidney Int 1999; 55 Suppl. 69: S131-4